AHR and inflammatory skin disease: Adding to the growing evidence of AHR’s beneficial activation in inflammatory skin disease, the development of tapinarof, a topical AHR modulating drug recently approved for psoriasis and effective also for atopic dermatitis (AD), offers a novel therapeutic option for patients with mild-to-moderate psoriasis and AD, harnessing the anti-inflammatory function of AHR [4].